Efficacy and safety of pralsetinib in patients with RET fusion positive non–small cell lung cancer: An observational real world study

•RET fusion accounted for1%-2% NSCLC.•Pralsetinib is effective for advanced NSCLC harboring RET fusion.•A favorable safety profile was observed for pralsetinib. Pralsetinib, a selective RET targeted tyrosine kinase inhibitor (TKI), has been approved for treating locally advanced or metastatic RET fusion-positive NSCLC in adults who have previously received platinum-based chemotherapy in China. In this retrospective analysis conducted at Hunan Cancer Hospital in China, we examined 36 patients with advanced NSCLC with RET fusion, who were treated with pralsetinib between January 2021 and December 2023. The study focused on assessing the efficacy (Progression-free survival (PFS) and overall survival (OS)) and safety profile of pralsetinib in these patients. Statistical analyses were conducted using SPSS version 20.0, with a significance level set at p